WebDisclosure WebDisclosure
Basculer en Français
10900 Companies
237551 Keywords
166488 Articles
127599 Press releases
Headlines Articles Press releases CELLNEX TELECOM S.A. Remove
  1. Home
  2. Companies
  3. CELLNEX TELECOM S.A.
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • PRESS RELEASE

    published on 08/24/2023 at 12:55, 3 years ago

    EQS-Adhoc: CELLNEX TELECOM S.A.: Optional Redemption Notice

    Logo of CELLNEX TELECOM S.A.
  • PRESS RELEASE

    published on 07/28/2023 at 21:05, 3 years 1 month ago

    EQS-Adhoc: CELLNEX TELECOM S.A.: The company announces the final terms and conditions of the convertible bond issuance and the repurchase of convertible bonds.

    Logo of CELLNEX TELECOM S.A.
  • PRESS RELEASE

    published on 07/28/2023 at 17:15, 3 years 1 month ago

    EQS-Adhoc: CELLNEX TELECOM S.A.: The company announces certain final terms and conditions of the convertible bond issue.

    Logo of CELLNEX TELECOM S.A.
  • PRESS RELEASE

    published on 07/28/2023 at 10:50, 3 years 1 month ago

    EQS-Adhoc: The company announces information regarding the issuance of a convertible bond and the repurchase of convertible bonds

    Logo of CELLNEX TELECOM S.A.
Accesswire
  • Published on 08/31/2026 at 17:22, 8 minutes ago

    ACCESS Newswire Expands the Marketplace with Two New Partners: TVEyes and Listicle Liaison

  • Published on 08/31/2026 at 15:50, 1 hour 40 minutes ago

    Sarama Resources - Grant of Equity Incentives

  • Published on 08/31/2026 at 15:00, 2 hours 30 minutes ago

    Super Copper Featured at OTC Markets' Virtual Investor Conference, Presentation Replay Now Available

  • Published on 08/31/2026 at 14:30, 3 hours ago

    Boron One Holdings Inc. Project Update

  • Published on 08/31/2026 at 14:30, 3 hours ago

    While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles

View all ACCESSWIRE
EQS Group
  • Published on 08/31/2026 at 16:40, 50 minutes ago

    Grêle : la Vaudoise se mobilise face à plus de 2’000 sinistres attendus

  • Published on 08/31/2026 at 16:09, 1 hour 20 minutes ago

    Mayr-Melnhof Karton AG: MM Group secures EcoVadis Platinum, ranking among global top 1 % for sustainability

  • Published on 08/31/2026 at 15:40, 1 hour 50 minutes ago

    EQS-Adhoc: SCP Standard Capital Partners AG expects to realize a book gain of approximately EUR 35 million from the acquisition of VANEA Technologies GmbH and Nocturne Technologies GmbH

  • Published on 08/31/2026 at 15:10, 2 hours 20 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.

  • Published on 08/31/2026 at 15:09, 2 hours 21 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: DCC plc

View all EQS
Les Echos
  • Published on 08/31/2026 at 15:00, 2 hours 30 minutes ago

    Déclaration mensuelle du nombre total de droits de vote et du nombre d’actions composant le capital

  • Published on 08/31/2026 at 12:00, 5 hours 30 minutes ago

    Capital increase through exercise of subscription rights

  • Published on 08/31/2026 at 12:00, 5 hours 30 minutes ago

    Kapitaalverhoging door uitoefening van inschrijvingsrechten

  • Published on 08/31/2026 at 07:00, 10 hours 30 minutes ago

    Biophytis strengthens its financial position and extends its cash runway into Q1 2027

  • Published on 08/31/2026 at 07:00, 10 hours 30 minutes ago

    Biophytis renforce sa situation financière et étend son horizon de trésorerie au T1 2027

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2026 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy